Methods of administering beta7 integrin antagonists

A technology of integrins and antagonists, applied in the fields of anti-inflammatory agents, immunoglobulins, chemical instruments and methods, etc., can solve problems such as inconvenience of patients

Inactive Publication Date: 2019-05-10
F HOFFMANN LA ROCHE & CO AG
View PDF60 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A limitation of vedolizumab therapy is that it is administered intravenously, which can be inconvenient for the patient and can also be associated with unwanted or adverse events such as infusion site reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of administering beta7 integrin antagonists
  • Methods of administering beta7 integrin antagonists
  • Methods of administering beta7 integrin antagonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0366] Phase I to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb β7 Administered in a Single-Dose, Dose-Escalation Phase Followed by a Multiple-Dose, Parallel Treatment Phase in Patients with Ulcerative Colitis , multicenter, randomized, placebo-controlled, double-blind study

[0367] research description

[0368] Description of rhuMAb β7 (etrolizumab)

[0369] rhuMAb β7 (etrolizumab) is a humanized monoclonal antibody based on human IgG1 subclass III V H , κ subtype-IV L Consensus sequence, and specificity against the β7 subunit of integrin heterodimers. It has been shown to bind α4β7 with high affinity (K of about 116 pM d ) and αEβ7 (K about 1800pM d ).

[0370]This recombinant antibody has two heavy chains (446 residues) and two light chains (214 residues) covalently linked by interchain and intrachain disulfide bonds typical of IgGl antibodies. For the studies described here, it was produced in Chi...

Embodiment 2

[0466] A phase II, randomized, double-blind, placebo-controlled study and an open-label extension study evaluating the efficacy and safety of rhumab beta7 in patients with moderate to severe ulcerative colitis

[0467] Research design

[0468] research description

[0469] This Phase II study is a randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two rhumab beta7 dose levels compared to placebo in patients with moderate to severe UC. This target patient population is the same as that studied in the Phase I study above. The primary efficacy endpoint will be assessed at Week 10 (2 weeks after the last dose of study drug) and the secondary efficacy endpoint will be assessed at Week 6.

[0470] rhuMAb β7 100 mg SC (fixed dose) at Weeks 0, 4 and 8 and 420 mg SC at Week 0 (flat loading dose) followed by 300 mg SC or matching placebo SC at Weeks 2, 4 and 8 within the dose range of 1 : Randomize patients in a 1:1 ratio. Research p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
Login to view more

Abstract

The invention relates to methods of administering beta7 integrin antagonists. Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohns disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.

Description

[0001] This application is a divisional application of an invention application with a filing date of March 30, 2012, a Chinese application number of 201280026685.6, and an invention title of "Method for Administering a β7 Integrin Antagonist". [0002] Cross References to Related Applications [0003] This application claims priority to Provisional US Application No. 61 / 470,360, filed March 31, 2011, and Provisional US Application No. 61 / 550,216, filed October 21, 2011, both of which are hereby incorporated by reference in their entireties. [0004] sequence listing [0005] This application contains a Sequence Listing that has been submitted in ASCII format via EFS-Web, which is hereby incorporated by reference in its entirety. This ASCII copy, created on March 15, 2012, is named P4622R1WO_SequenceListing.txt and is 17,964 bytes in size. technical field [0006] Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcera...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K9/00A61K39/395A61P1/00A61P29/00
CPCC07K16/2839A61K2039/505A61K2039/54A61K2039/545A61K2039/55C07K2317/24C07K2317/92A61P1/00A61P1/04A61P29/00A61P37/00A61K31/196A61K31/519A61K31/52A61K39/3955
Inventor B·阿南德S·奥伯恩E·斯特法尼奇M·唐J·维施M·威廉姆斯
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap